Found vs Hers: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

Found and Hers are tied at 7.3/10. Hers is more affordable at $199/mo vs $264/mo. Choose Found for users who want a science-backed weight loss program with beh. Choose Hers for women who want brand-name wegovy (injection or pill) at $149.

A side-by-side comparison of Found and Hers covering pricing, scores, medication types, insurance, and more to help you decide.

Found

#37 of 48

7.3/10

Science-backed weight management platform combining GLP-1 medications with behavioral health coaching and support.

Visit Found

Hers

#35 of 48

7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.

Visit Hers

Feature	Found	Hers
Our Score	7.3/10	7.3/10
Starting Price	$264/mo	$199/mo
Medication Type	Both	Both
Insurance Accepted	Yes	No
Best For	Users who want a science-backed weight loss program with behavior change support	Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand
Ranking	#37	#35

Pros & Cons Compared

Found

Pros

+Active insurance coordination — Found contacts your insurer and reports which GLP-1s are covered, prior auth requirements, and estimated copay
+10+ medication options including both compounded and brand-name (Wegovy, Zepbound, Wegovy pill) — the widest formulary of any platform
+Typical insured copay of ~$30/mo for most members — dramatically lower than cash-pay alternatives
+Most members start treatment within one week of completing the health questionnaire

Cons

−Pricing is less transparent than flat-rate competitors — costs vary by insurance status and medication choice
−The insurance navigation process adds steps and complexity compared to simple cash-pay platforms
−Compounded medication availability may shift with FDA enforcement changes

Hers

Pros

+2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
+Zepbound access via the Lilly/Hims-Hers partnership announced 2026
+Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
+Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services

Cons

−Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
−Generic support experience — large patient volume means less personalized attention
−Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
−Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value

Our Verdict

Found and Hers are closely matched with identical scores of 7.3/10. If budget is your priority, Hers starts at $199/mo compared to Found's $264/mo. Found accepts insurance, which can significantly reduce your out-of-pocket costs. Choose Found if you want: users who want a science-backed weight loss program with behavior change support. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Found nor Hers feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review